Dr.ย Caicunย Zhou
MD, PhD
Professor & Director, Department of Oncology
corporate_fareShanghai Pulmonary Hospital, Tongji University
Caicun Zhou
MD, PhD
Prof. Caicun Zhou is one of China's most distinguished lung cancer oncologists and serves as Professor and Director of the Department of Oncology at Shanghai Pulmonary Hospital affiliated with Tongji University. He brings nearly 30 years of clinical experience to the diagnosis and systemic treatment of lung cancer, with expertise in early detection, targeted therapy, immunotherapy, and precision treatment planning.
Prof. Zhou completed visiting scientist training at MD Anderson Cancer Center in 2002 and earlier research training in Japan before building his career at Shanghai Pulmonary Hospital, one of China's major specialist centres for thoracic oncology. He has been involved in landmark clinical trials โ including OPTIMAL, HARMONi-2, and PAPILLON โ that have shaped international treatment standards for EGFR-mutated and PD-L1-positive non-small cell lung cancer. The official hospital profile reports that he has authored more than 300 papers, including over 100 SCI-indexed articles, and holds five national invention patents. In 2023, Prof. Zhou became the first expert from mainland China to be elected IASLC President-designate, and he serves as IASLC President for 2025โ2027. His team received the IASLC Cancer Care Team Award in 2022, recognised as the only Asian team among four global award winners that year.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Zhou at Shanghai Pulmonary Hospital, subject to hospital availability and case acceptance.
Why Consider Prof. Caicun Zhou?
Prof. Zhou combines nearly 30 years of clinical expertise in lung cancer with global research leadership, making him one of the most sought-after oncologists for advanced NSCLC, EGFR-mutated lung cancer, and immunotherapy-based treatment.
Areas of Specialization
Precision systemic oncology for lung cancer and NSCLC
Prof. Zhou's clinical practice is centred on modern precision oncology for lung cancer, matching treatment to molecular markers, tumour biology, and patient-specific needs.
Immunotherapy
PD-1 and PD-L1 checkpoint inhibitor strategies for suitable lung cancer patients.
- arrow_rightPD-1 / PD-L1 inhibitors for PD-L1-positive NSCLC
- arrow_rightImmunotherapy-based first-line treatment strategies
- arrow_rightCombination immunotherapy and chemotherapy protocols
- arrow_rightHARMONi-2 trial: ivonescimab vs pembrolizumab in PD-L1-positive advanced NSCLC
- arrow_rightBiomarker-driven patient selection for immunotherapy
Targeted Therapy
Molecularly guided treatment for EGFR-mutated and driver-positive NSCLC.
- arrow_rightEGFR TKIs for first-line and subsequent lines in EGFR-mutated NSCLC
- arrow_rightOPTIMAL trial: erlotinib vs chemotherapy in EGFR mutation-positive NSCLC
- arrow_rightManagement of EGFR exon 20 insertion mutations
- arrow_rightAnti-angiogenic agents combined with systemic therapy for NSCLC
- arrow_rightCombination strategies using anti-angiogenesis and targeted agents
Early Diagnosis & Comprehensive Treatment
Early-stage lung cancer detection and individualised multimodality management.
- arrow_rightEarly detection strategies for lung cancer
- arrow_rightComprehensive staging and molecular profiling
- arrow_rightIndividualised treatment planning based on stage and biology
- arrow_rightMultimodality treatment planning for advanced lung cancer
- arrow_rightPersonalised therapy selection based on pathology and biomarkers
Procedures Performed
Systemic and precision oncology services for lung cancer
Prof. Zhou's clinical services span the full lung cancer care pathway, from early diagnosis and molecular staging through first-line systemic therapy, resistance management, and clinical trial-based treatment.
Lung Cancer Medical Oncology
Medical OncologyComprehensive systemic treatment planning and administration for lung cancer, integrating chemotherapy, immunotherapy, and targeted therapy based on tumour biology.
Targeted Therapy for NSCLC
Targeted TherapyMolecularly driven targeted treatment for driver-positive non-small cell lung cancer including EGFR-mutated and exon 20 insertion subtypes.
Comprehensive Staging & Diagnosis
DiagnosisThorough molecular and imaging evaluation to guide treatment selection for lung cancer patients.
Treatment Monitoring & Follow-Up
MonitoringOngoing assessment of treatment response and disease progression for lung cancer patients.
Second Opinion Consultations
Second OpinionExpert independent review for patients with complex or advanced lung cancer seeking a specialist opinion.
Research & Publications
International clinical trial leadership and peer-reviewed contributions
Prof. Zhou has published more than 300 papers including over 100 SCI-indexed articles across leading international journals, and has contributed to landmark lung cancer clinical trials that have influenced global treatment guidelines.
Prof. Zhou's full publication list is available via Google Scholar and PubMed. CancerFax can assist with sourcing relevant research publications on request.
Education & Training
Prof. Zhou completed medical training in China and Japan, and undertook a visiting scientist fellowship at MD Anderson Cancer Center in the United States. His formal academic qualifications are MD and PhD. Specific undergraduate and postgraduate institutions were not publicly verified in accessible sources.
Clinical Experience
Prof. Zhou has built a career spanning nearly 30 years in lung cancer oncology, progressing from clinical roles at Bengbu Medical College to leading the Oncology Department at Shanghai Pulmonary Hospital, one of China's foremost specialist thoracic centres.
Languages & International
Prof. Zhou consults in Chinese. English-language communication has not been formally verified from official sources.
CancerFax provides professional medical interpreter support to facilitate consultations with Prof. Zhou for non-Chinese-speaking patients.
CancerFax can coordinate professional medical interpreter support for international patients consulting Prof. Zhou.
How CancerFax Helps You Access Dr. Caicun Zhou
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Caicun Zhou's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Caicun Zhou's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Caicun Zhou before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Caicun Zhou's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Caicun Zhou's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Caicun Zhou's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Caicun Zhou
Prof. Zhou specialises in lung cancer, with particular focus on non-small cell lung cancer (NSCLC), advanced and metastatic NSCLC, EGFR-mutated NSCLC, EGFR exon 20 insertion NSCLC, and PD-L1-positive NSCLC. His clinical work also includes thoracic oncology more broadly.
Prof. Zhou is Director of the Department of Oncology at Shanghai Pulmonary Hospital affiliated with Tongji University in Shanghai, China โ one of China's leading specialist centres for lung disease and thoracic oncology.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review the documents, prepare the case for submission, and coordinate the next steps with the hospital, subject to availability and case acceptance.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Zhou, subject to hospital availability and case acceptance. Please submit your reports through CancerFax to begin the process.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, molecular profiling results, treatment history, and relevant test results. The final consultation format and availability depend on the doctor's institution and scheduling.
Prof. Zhou's verified treatment expertise includes EGFR-targeted therapy, checkpoint inhibitor immunotherapy (PD-1 / PD-L1 inhibitors), anti-angiogenesis therapy, chemotherapy, and individualised comprehensive treatment planning. His approach is guided by molecular profiling and tumour biology, as highlighted by Shanghai Pulmonary Hospital.
Prof. Caicun Zhou was elected IASLC President-designate for 2023โ2025 and IASLC President for 2025โ2027, becoming the first expert from mainland China to hold this leadership role in the International Association for the Study of Lung Cancer. His team also received the IASLC Cancer Care Team Award in 2022, recognised as the only Asian team among four global winners that year.
Connect with Caicun Zhou Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.